{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:21:48Z","timestamp":1783635708144,"version":"3.55.0"},"publisher-location":"New York, NY","reference-count":20,"publisher":"Springer US","isbn-type":[{"value":"9781071650493","type":"print"},{"value":"9781071650509","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5050-9_7","type":"book-chapter","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:03:05Z","timestamp":1783634585000},"page":"81-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Androgen Receptor Variant 7 (AR-V7) Transcript Expression in Circulating Tumor Cells"],"prefix":"10.1007","author":[{"given":"Tanzila","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bavanthi","family":"Balakrishnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese M.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"2","key":"7_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. J Am Med Assoc 294(2):238\u2013244","journal-title":"J Am Med Assoc"},{"issue":"4","key":"7_CR2","first-page":"336","volume":"30","author":"J Luo","year":"2016","unstructured":"Luo J, Beer TM, Graff JN (2016) Treatment of nonmetastatic castration-resistant prostate cancer. Oncology 30(4):336\u2013336","journal-title":"Oncology"},{"issue":"12","key":"7_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15(12):701\u2013711","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69(1):16\u201322","journal-title":"Cancer Res"},{"key":"7_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-015-0490-9","volume":"18","author":"T Zhang","year":"2016","unstructured":"Zhang T, Armstrong AJ (2016) Clinical utility of circulating tumor cells in advanced prostate cancer. Curr Oncol Rep 18:1\u20138","journal-title":"Curr Oncol Rep"},{"key":"7_CR6","doi-asserted-by":"crossref","unstructured":"Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila DJJo (2016) Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2(11):1441\u20131449","DOI":"10.1001\/jamaoncol.2016.1828"},{"issue":"4","key":"7_CR7","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3390\/cancers5041676","volume":"5","author":"B Hu","year":"2013","unstructured":"Hu B, Rochefort H, Goldkorn A (2013) Circulating tumor cells in prostate cancer. Cancers 5(4):1676\u20131690","journal-title":"Cancers"},{"key":"7_CR8","doi-asserted-by":"crossref","unstructured":"Ma Y, Luk A, Young FP, Lynch D, Chua W, Balakrishnar B, De Souza P, Becker TM (2016) Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patient blood biopsies. Int J Mol Sci 17(8):1264","DOI":"10.3390\/ijms17081264"},{"issue":"1","key":"7_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20079-w","volume":"12","author":"T Khan","year":"2022","unstructured":"Khan T, Lock JG, Ma Y, Harman DG, de Souza P, Chua W, Balakrishnar B, Scott KF, Becker TM (2022) Choice of antibody is critical for specific and sensitive detection of androgen receptor splice variant-7 in circulating tumor cells. Sci Rep 12(1):16159. https:\/\/doi.org\/10.1038\/s41598-022-20079-w","journal-title":"Sci Rep"},{"issue":"3","key":"7_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1373\/clinchem.2017.281295","volume":"64","author":"A El-Heliebi","year":"2018","unstructured":"El-Heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E, Kroneis T, Chen S, Smolle M, Rossmann C (2018) In situ detection and quantification of AR-V7, AR-FL, PSA, and KRAS point mutations in circulating tumor cells. Clin Chem 64(3):536\u2013546","journal-title":"Clin Chem"},{"issue":"1","key":"7_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12139-3","volume":"24","author":"HE Liu","year":"2024","unstructured":"Liu HE, Vuppalapaty M, Hoerner CR, Bergstrom CP, Chiu M, Lemaire C, Che J, Kaur A, Dimmick A, Liu S (2024) Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest. BMC Cancer 24(1):482","journal-title":"BMC Cancer"},{"key":"7_CR12","doi-asserted-by":"crossref","unstructured":"Khan T, Becker TM, Scott KF, Descallar J, de Souza P, Chua W, Ma Y (2022) Prognostic and predictive value of liquid biopsy-derived androgen receptor variant 7 (AR-V7) in prostate cancer: a systematic review and meta-analysis. Front Oncol 12:868031","DOI":"10.3389\/fonc.2022.868031"},{"key":"7_CR13","doi-asserted-by":"crossref","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028\u20131038","DOI":"10.1056\/NEJMoa1315815"},{"issue":"13","key":"7_CR14","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1200\/JCO.18.01731","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, Chen Y, Silberstein JL, Kemeny G, Galletti G, Somarelli JA, Gupta S, Gregory SG, Scher HI, Dittamore R, Tagawa ST, Antonarakis ES, George DJ (2019) Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J Clin Oncol 37(13):1120\u20131129. https:\/\/doi.org\/10.1200\/JCO.18.01731","journal-title":"J Clin Oncol"},{"key":"7_CR15","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/PO.20.00200","volume":"4","author":"AJ Armstrong","year":"2020","unstructured":"Armstrong AJ, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand\u00a0M, Berry WR, Zhang T (2020) Prospective multicenter study of circulating tumor cell AR-V7 and taxane versus hormonal treatment outcomes in metastatic castration-resistant prostate cancer. JCO Precis Oncol 4:1285\u20131301","journal-title":"JCO Precis Oncol"},{"key":"7_CR16","doi-asserted-by":"crossref","unstructured":"Scher HI, Graf RP, Schreiber NA, Jayaram A, Winquist E, McLaughlin B, Lu D, Fleisher M, Orr S, Lowes L (2018) Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA Oncol 4(9):1179\u20131186","DOI":"10.1001\/jamaoncol.2018.1621"},{"issue":"5","key":"7_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","volume":"1","author":"ES Antonarakis","year":"2015","unstructured":"Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA (2015) Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 1(5):582\u2013591","journal-title":"JAMA Oncol"},{"issue":"5","key":"7_CR18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/ijms18051047","volume":"18","author":"AW Luk","year":"2017","unstructured":"Luk AW, Ma Y, Ding PN, Young FP, Chua W, Balakrishnar B, Dransfield DT, de Souza P, Becker TM (2017) CTC-mRNA (AR-V7) analysis from blood samples\u2014impact of blood collection tube and storage time. Int J Mol Sci 18(5):1047","journal-title":"Int J Mol Sci"},{"key":"7_CR19","doi-asserted-by":"publisher","first-page":"184945441878261","DOI":"10.1177\/1849454418782617","volume":"7","author":"JW Po","year":"2018","unstructured":"Po JW, Roohullah A, Lynch D, DeFazio A, Harrison M, Harnett PR, Kennedy C, de Souza P, Becker TM (2018) Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. J Circ Biomark 7:1849454418782617","journal-title":"J Circ Biomark"},{"key":"7_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fonc.2012.00131","volume":"2","author":"E Diamond","year":"2012","unstructured":"Diamond E, Lee GY, Akhtar NH, Kirby BJ, Giannakakou P, Tagawa ST, Nanus DM (2012) Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol 2:131","journal-title":"Front Oncol"}],"container-title":["Methods in Molecular Biology","Circulating Tumor Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5050-9_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:03:06Z","timestamp":1783634586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5050-9_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071650493","9781071650509"],"references-count":20,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5050-9_7","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"3 June 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}